Translational Development Acquisition Corp. (TDACU) EBIT (2024 - 2026)
Translational Development Acquisition's (TDACU) quarterly EBIT came in at -$281161.0 in Q1 2026, up 19.07% YoY from -$236133.0 in Q1 2025, and down 73.19% on a QoQ basis from -$162345.0 in Q4 2025.
Translational Development Acquisition Corp. (TDACU) EBIT (2024 - 2026) Analysis & Trends
Translational Development Acquisition (TDACU) has 3 years of EBIT data on file, last reported at -$281161.0 in Q1 2026.
- Quarterly EBIT rose 19.07% year-over-year to -$281161.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$878291.0 (changed N/A YoY) and the FY2025 annual result came in at -$944538.0, down 381.03% from the prior year.
- EBIT declined to -$281161.0 in Q1 2026, from -$162345.0 in the prior quarter.
- In the past five years, EBIT ranged from a high of -$61283.0 in Q3 2024 to a low of -$347408.0 in Q1 2025.
- A 3-year average of -$202910.3 and a median of -$213658.0 in 2025 frame the typical range for EBIT.
- Annual changes were most pronounced in 2025 — EBIT slumped 248.64% — and 2026, when it grew 19.07%.
- Tracing TDACU's EBIT over 3 years: stood at -$133390.0 in 2024, then retreated by 21.71% to -$162345.0 in 2025, then sank by 73.19% to -$281161.0 in 2026.
- The last three EBIT figures came in at -$281161.0 (Q1 2026), -$162345.0 (Q4 2025), and -$213658.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -281,161.00 |
| Dec 31, 2025 | -162,345.00 |
| Sep 30, 2025 | -213,658.00 |
| Jun 30, 2025 | -221,127.00 |
| Mar 31, 2025 | -347,408.00 |
| Dec 31, 2024 | -133,390.00 |
| Sep 30, 2024 | -61,283.00 |